Navigation Links
Genome of CHO-K1 provides new insights into optimization of biopharmaceutical protein production
Date:8/1/2011

August 1st, 2011, Shenzhen, China and San Diego, CA BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published online in Nature Biotechnology. The CHO-K1 genome is the first published cell line genome decoded by de novo sequencing and assembly. The study yields a better understanding of the genetics of CHO cells and will accelerate the discovery and development of new recombinant protein therapies.

Chinese hamster ovary (CHO) cell lines are mammalian cells derived from the ovary of the Chinese hamster and are the preferred and most commonly used mammalian hosts today in biological and medical research. These cell lines play an important role in bioprocessing research and the development of therapeutic biopharmaceuticals. Currently the worldwide market for recombinant therapeutic proteins totals more than 99 billion USD in annual revenue from a broad range of products, including monoclonal antibodies, growth factors, hormones, and blood factors.

"Recognizing the importance of CHO cell lines, we and our partners jointly initiated a study of the genome sequence of CHO-K1 cells," said co-leading author of the study Xun Xu, Vice President of Research and Development at BGI and CEO BGI Americas. "The genome sequence and comprehensive annotation of the CHO-K1 cell line provides a useful and powerful tool for scientists in biomedical areas to optimize the production process and improve the yield of therapeutic proteins," he added.

GT Life Sciences' established business platform for metabolic modeling and engineering of mammalian cells has already proven effective in optimizing CHO cell media and developing novel selectable markers. With the advanced genome sequencing capability of BGI, the CHO-K1 ancestral cell line was sequenced by de novo sequencing and then assembled by BGI's Short Oligonucleotide Analysis Package, SOAPdenovo, resulting in the assembly of 2.45 Gb of the genomic sequence. This information was combined with transcriptome sequence data and led to the generation of 24,383 predicted genes.

"After working with cell culture for over 20 years, this is a dream come true," said Bernhard Palsson, Ph.D., co-founder of GT Life Sciences. "We can now hope to develop metabolic and cell line engineering procedures that approach those currently available for E. coli and yeast. This development signifies the start of genome-scale science for CHO."

"The CHO cell line genome revealed the secret of its protein synthesis, modification and viral resistance, which are very unique among other cell lines and make it the optimal protein production tool." said Xu. Because of the fact that differential glycosylation can substantially affect functional activity and immune responses, researchers carried out a genome-scale assessment of CHO-K1 genes involved in protein glycosylation pathways. They identified homologs to 99% of the human glycosylation-associated genes in the CHO-K1 genome, with 53% of them expressed. The high coverage of homologs provides a unique opportunity for glycoform manipulation in CHO cells. According to the report, the genome of CHO-K1 also provided insight into viral susceptibility genes and found that key genes associated with viral entry are not expressed in CHO-K1.

"Coupling the CHO sequence with a complete genome-scale model of CHO metabolism will prove highly productive in our ability to deliver next-generation process technologies for biopharmaceutical production in CHO and other mammalian cell lines," added Iman Famili, Ph.D., Sr. Director, Research and Development at GT Life Sciences.

"The CHO-K1 genome provides the foundation for studies of other CHO cell lines and is a major step forward in the application of genomics in the production of biopharmaceuticals," stated Dr. Jun Wang, Executive Director of BGI. "We expect that cell line engineering will be facilitated by genomics applications and the biopharmaceutical industry as well human healthcare will gain great benefits."


'/>"/>

Contact: Jia Liu
liujia@genomics.cn
342-874-8918
Beijing Genomics Institute
Source:Eurekalert

Related biology news :

1. Dissecting the genomes of crop plants to improve breeding potential
2. Genome-wide study reveals 3 new susceptibility loci for adult asthma in Japanese population
3. Mitochondrial genome mutates when reprogrammed
4. BGI develops new strategy to uncover structural variations of human genomes
5. BGI and National Wolfberry Engineering Research Center launch Chinese wolfberry genome project
6. The first studies utilizing the Collaborative Cross mice are published in Genome Research
7. BGI contributes whole genome sequencing and bioinformatics expertise to potato genome research
8. Simple little spud helps scientists crack potatos mighty genome
9. UW-Madison scientists played role in potato genome project
10. First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conference
11. Genome analysis will reveal how bacteria in our guts make themselves at home
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
Breaking Biology News(10 mins):
(Date:6/26/2017)... ... June 26, 2017 , ... Two new members were ... Meeting on June 9, 2017: Jeremy Nowak, President, J Nowak Strategy and Michele Masucci, ... announced the election of Glen N. Gaulton and Kenneth L. Kring, and re-election of ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... all six of their healthcare job boards. As the largest network of ... therapists, and biotechnicians, DocCafe.com and the MedJobCafe.com Health Network work to match ...
(Date:6/22/2017)... , ... June 21, 2017 , ... Building on the ... inspiring, and more informative on the very latest developments in radical life extension. RAADfest ... of a festival, and the empowerment of personal development, making it the largest most ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell Consulting’s ... biopharma and life sciences industries, continue to be in demand for their insights ... will be speaking on “The State of Information Governance in the Biopharmaceutical Industry” ...
Breaking Biology Technology: